Oculis Holding AG (NASDAQ:OCS - Get Free Report) was down 3% during trading on Wednesday . The stock traded as low as $18.52 and last traded at $18.41. Approximately 7,333 shares were traded during mid-day trading, a decline of 84% from the average daily volume of 45,398 shares. The stock had previously closed at $18.97.
Wall Street Analysts Forecast Growth
A number of research analysts have recently commented on OCS shares. Robert W. Baird upped their price target on Oculis from $37.00 to $41.00 and gave the stock an "outperform" rating in a report on Thursday, March 13th. HC Wainwright cut their target price on shares of Oculis from $30.00 to $29.00 and set a "buy" rating for the company in a research note on Thursday, March 13th. Finally, Chardan Capital restated a "buy" rating and issued a $28.00 price target on shares of Oculis in a research report on Thursday, March 13th.
Read Our Latest Stock Report on Oculis
Oculis Trading Down 0.4 %
The company has a 50 day moving average of $20.95 and a 200 day moving average of $17.26. The firm has a market cap of $854.47 million, a price-to-earnings ratio of -10.14 and a beta of 0.01. The company has a current ratio of 4.02, a quick ratio of 4.02 and a debt-to-equity ratio of 0.01.
Oculis (NASDAQ:OCS - Get Free Report) last issued its earnings results on Tuesday, March 11th. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.28). Oculis had a negative net margin of 8,043.28% and a negative return on equity of 71.31%. As a group, research analysts anticipate that Oculis Holding AG will post -2.09 EPS for the current year.
Institutional Trading of Oculis
Several large investors have recently added to or reduced their stakes in OCS. Geode Capital Management LLC lifted its position in shares of Oculis by 12.0% during the fourth quarter. Geode Capital Management LLC now owns 16,744 shares of the company's stock worth $284,000 after purchasing an additional 1,800 shares in the last quarter. Bellevue Group AG bought a new stake in shares of Oculis in the 4th quarter valued at $170,000. Bank of America Corp DE increased its holdings in shares of Oculis by 58.2% in the fourth quarter. Bank of America Corp DE now owns 28,980 shares of the company's stock worth $493,000 after acquiring an additional 10,667 shares in the last quarter. XTX Topco Ltd bought a new position in Oculis in the fourth quarter valued at approximately $225,000. Finally, Citadel Advisors LLC bought a new stake in Oculis in the 4th quarter valued at $389,000. 22.30% of the stock is owned by institutional investors.
Oculis Company Profile
(
Get Free Report)
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
Featured Articles
Before you consider Oculis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oculis wasn't on the list.
While Oculis currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
